Portage Biotech (NASDAQ:ALP) Research Coverage Started at HC Wainwright

HC Wainwright initiated coverage on shares of Portage Biotech (NASDAQ:ALP) in a report published on Monday, MarketBeat reports. The brokerage issued a neutral rating and a $0.25 price objective on the stock. HC Wainwright also issued estimates for Portage Biotech’s Q1 2027 earnings at ($0.10) EPS, Q2 2027 earnings at ($0.07) EPS, Q3 2027 earnings at ($0.07) EPS, Q4 2027 earnings at ($0.06) EPS, FY2027 earnings at ($0.28) EPS, Q1 2028 earnings at ($0.04) EPS, Q2 2028 earnings at ($0.04) EPS, Q3 2028 earnings at ($0.04) EPS, Q4 2028 earnings at ($0.04) EPS and FY2028 earnings at ($0.17) EPS.

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Portage Biotech in a research note on Friday, July 24th. One analyst has rated the stock with a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Reduce” and an average target price of $0.25.

Portage Biotech Trading Down 7.1%

Shares of NASDAQ ALP opened at $0.15 on Monday. Portage Biotech has a fifty-two week low of $0.14 and a fifty-two week high of $13.80. The firm has a market capitalization of $3.54 million, a P/E ratio of -0.02 and a beta of 0.61. The company has a debt-to-equity ratio of 0.01, a current ratio of 0.31 and a quick ratio of 0.31. The company’s 50 day simple moving average is $0.28 and its 200 day simple moving average is $0.34.

Portage Biotech (NASDAQ:ALP) last released its earnings results on Thursday, July 16th. The company reported $0.48 EPS for the quarter. The business had revenue of $0.05 million for the quarter. On average, analysts predict that Portage Biotech will post -0.28 EPS for the current year.

Trending Headlines about Portage Biotech

Here are the key news stories impacting Portage Biotech this week:

• Positive Sentiment: HC Wainwright’s $0.25 price target is above Portage Biotech’s recent trading level, suggesting meaningful theoretical upside if the company executes on its development plans. The firm also expects losses to narrow from an estimated $(0.28) per share in fiscal 2027 to $(0.17) in fiscal 2028.
• Neutral Sentiment: HC Wainwright forecasts quarterly losses of $(0.10), $(0.07), $(0.07), and $(0.06) per share for fiscal 2027, resulting in a $(0.28) full-year loss. For fiscal 2028, the analyst projects a relatively consistent $(0.04) quarterly loss and a $(0.17) annual loss, indicating gradual improvement but no expected profitability in the forecast period. Portage Biotech analyst estimates
• Negative Sentiment: The Neutral rating and continuing projected losses may limit investor enthusiasm. Portage Biotech has also experienced substantial share-price weakness, trading close to its one-year low, while its latest reported quarterly revenue was only $0.05 million.

About Portage Biotech

Portage Biotech (NASDAQ:ATON) is a biotechnology company focused on acquiring, developing and advancing therapeutic candidates and platform technologies. The company concentrates its development efforts primarily in areas such as oncology, immunology/inflammation and infectious disease, seeking to move programs from discovery and preclinical stages into clinical development through subsidiary companies and collaborative arrangements.

Portage structures its operations to support a diversified pipeline, advancing both small molecules and biologics by funding preclinical research, conducting clinical trials, and managing regulatory interactions.